诺和诺德崩跌近20%！下一代减肥药数据不及预期礼来闻讯大涨

东方财富12-20 20:55

被誉为“减肥药双雄”的诺和诺德，周五给全球投资者表演了一把“高位跳水”。由于备受期待的“下一代减肥药”数据不佳，截至发稿公司美股盘前一度下跌超20%——基本把2023年7月以后的涨幅全部回吐了。（诺和诺德日线图）诺和诺德周五官网发布的公告显示，备受期待的复方合剂CagriSema（2.4毫克卡格列肽+2.4毫克司美格鲁肽），在试验对象坚持使用68周后，CagriSema组平均减重22.7%。作为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492106410?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-20 20:55","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2492106410","market":"us","top_or_hot":-1,"title":"诺和诺德崩跌近20%！下一代减肥药数据不及预期 礼来闻讯大涨","media":"东方财富","content":"<div>\n<p>被誉为“减肥药双雄”的诺和诺德，周五给全球投资者表演了一把“高位跳水”。由于备受期待的“下一代减肥药”数据不佳，截至发稿公司美股盘前一度下跌超20%——基本把2023年7月以后的涨幅全部回吐了。（诺和诺德日线图）诺和诺德周五官网发布的公告显示，备受期待的复方合剂CagriSema（2.4毫克卡格列肽+2.4毫克司美格鲁肽），在试验对象坚持使用68周后，CagriSema组平均减重22.7%。作为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205556a1fde9b6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德崩跌近20%！下一代减肥药数据不及预期 礼来闻讯大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德崩跌近20%！下一代减肥药数据不及预期 礼来闻讯大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 20:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205556a1fde9b6&s=b><strong>东方财富</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>被誉为“减肥药双雄”的诺和诺德，周五给全球投资者表演了一把“高位跳水”。由于备受期待的“下一代减肥药”数据不佳，截至发稿公司美股盘前一度下跌超20%——基本把2023年7月以后的涨幅全部回吐了。（诺和诺德日线图）诺和诺德周五官网发布的公告显示，备受期待的复方合剂CagriSema（2.4毫克卡格列肽+2.4毫克司美格鲁肽），在试验对象坚持使用68周后，CagriSema组平均减重22.7%。作为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205556a1fde9b6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205556a1fde9b6&s=b","article_id":"2492106410","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205556a1fde9b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2492106410","pubTimestamp":1734699338,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"被誉为“减肥药双雄”的诺和诺德，周五给全球投资者表演了一把“高位跳水”。作为参照，安慰剂组减重数据为2.3%。分析师们普遍预期，CagriSema有望在2026年上市，接班司美格鲁肽成为诺和诺德下一代营收引擎。对于诺和诺德来说，更紧迫的问题是与礼来的竞争。受此消息带动，礼来周五盘前大涨近10%。值得一提的是，诺和诺德在今年9月时，也因为口服减肥药Monlunabant的试验数据不理想出现过单日大跌。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","NVO":"诺和诺德","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LLY":"礼来","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC"},"translate_title":"Novo Nordisk collapsed nearly 20%! Next-generation diet pill data falls short of expectations, Eli Lilly surges after hearing the news","themeId":"4de5f7200a34a5a69d5dce1d967bfe14","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"LLY":1},"content_text":"被誉为“减肥药双雄”的诺和诺德，周五给全球投资者表演了一把“高位跳水”。由于备受期待的“下一代减肥药”数据不佳，截至发稿公司美股盘前一度下跌超20%——基本把2023年7月以后的涨幅全部回吐了。（诺和诺德日线图）诺和诺德周五官网发布的公告显示，备受期待的复方合剂CagriSema（2.4毫克卡格列肽+2.4毫克司美格鲁肽），在试验对象坚持使用68周后，CagriSema组平均减重22.7%。作为对比，单独接受卡格列肽治疗的患者减重11.8%、单独接受司美格鲁肽治疗的患者减重16.1%。作为参照，安慰剂组减重数据为2.3%。问题在于，诺和诺德在11月公布三季报时曾重申，CagriSema的减重效果能够达到25%，比起诺和盈（Wegovy）的15%显著提升。分析师们普遍预期，CagriSema有望在2026年上市，接班司美格鲁肽成为诺和诺德下一代营收引擎。对于诺和诺德来说，更紧迫的问题是与礼来的竞争。本月早些时候，礼来公布的头对头试验结果显示，Zepbound（替尔泊肽注射液）使用72周的平均减重效果达到20.2%，显著高于Wegovy的13.7%。在今年8月的另一项研究中，Zepbound在使用176周后的减重效果能达到22.9%。而从效果上来看，礼来这款已经获批上市的药物，效果直逼诺和诺德至少两年后才能推出的新药。受此消息带动，礼来周五盘前大涨近10%。更“扎心”的是，美国FDA周四才刚刚宣布，Zepbound在美国市场已经不再短缺。值得一提的是，诺和诺德在今年9月时，也因为口服减肥药Monlunabant的试验数据不理想出现过单日大跌。（文章来源：财联社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492106410"}

诺和诺德崩跌近20%！下一代减肥药数据不及预期 礼来闻讯大涨

精彩评论

诺和诺德崩跌近20%！下一代减肥药数据不及预期礼来闻讯大涨